ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1161

Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity

Adriana Miguel-Álvarez1, luis M Amezcua Guerra2, María L Loredo-Mendoza1, Luis H. Silveira Torre3 and Angélica Vargas Guerrero4, 1Instituto Nacional de Cardiología "Ignacio Chávez", México, Distrito Federal, Mexico, 2Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, 3Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, 4Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico

Meeting: ACR Convergence 2024

Keywords: Autoantibody(ies), dermatomyositis, Myopathies, Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The aim of this study is to assess if there are clinical and serological differences in patients with idiopathic inflammatory myopathies (IIM) according to multiple versus single positivity myositis specific antibodies (MSA) determined by line immunoassay (LIA). In patients with muscle biopsy, differences between groups were also analyzed.

Methods: We retrospectively reviewed all the patients who satisfy 2017 EULAR/ACR classification criteria for adult and juvenile IIM and who had MSA panel by LIA between March 2023 and May 2024. Due to the number of patients, only anti-Mi2 and anti-TIF1γ were subanalyzed. Chi-square, Fisher’s, Mann-Whitney U and Kruskall Wallis tests were used for association between groups. Two-tail p value < 0.05 was considered statistically significant.

Results: Fifty-seven patients were included; forty-two (73%) female. IIM diagnosis distribution is in table 1. Fifty-four patients (94.7%) had ≥1 MSA; thirty-seven (64.9%) were single MSA positive and 17 (29.8%) multiple. Anti-Mi2 was the most common MSA, it was present in 25 patients (44%), followed by anti-TIF1γ in 17 (30%), anti-MDA5 in 12 (21%), anti-SRP in 9 (16%), anti-SAE in 8 (12%), anti-Jo-1 and anti-PL-7 7 each one (12%), anti-PL-12 in 5 (9%), anti-OJ in 4 (7%), anti-NXP2 and anti-EJ 2 each one (3%). In general, no differences in activity were observed between groups (table 1). Initial LDH levels were higher in patients with single MSA positivity; in those with multiple positivity, the use of prednisone and comorbidities were more frequent. Anti-PM/Scl 75 and anti-Ku were present only in multiple positivity group (table 1). Twenty-eight patients (49.1%) had muscle biopsy available. Perifascicular atrophy was identified in single MSA positivity group, while chronic endomysial infiltrate in multiple positivity (figure 1). Heliotrope rash and nail dystrophy were more frequent in negative anti-Mi2; while positive anti-Mi2 was related with dysphagia. Lower MMT-8 scores and higher creatin kinase levels were observed in high positive anti-Mi2 (table 2). Patients with strongly positive anti-TIF1γ had lower LDH and C reactive protein. Dermatological features were more frequent in stronger positive anti- TIFγ antibodies (table 2); the 6 patients with low positive anti-TIF1y antibodies had hypothyroidism and 2 had breast cancer

Conclusion: Strong positivity by LIA seems to have greater clinical and serological correlations, as anti-Mi2 and anti-TIF1γ in this study. Few differences were found between multiple positivity versus single positivity MSA: glucocorticoid use and comorbidities were more frequent in the former. Presence of anti-PM/Scl 75, anti-Ku and endomysial chronic infiltration was present only in multiple MSA. Studies with more patients are required to evaluate if there are clinical and histological differences in patients with one or multiple MSA, including comparisons with specific tests as ELISA.

Supporting image 1

Supporting image 2

Figure 1. Four cases of inflammatory myopathy photomicrographs. A and B show two cases with endomysial lymphocytic inflammatory infiltrate (arrows) and degenerative myocyte changes accompanied by phagocytic macrophages (arrow heads) C and D depict perimysial mononuclear inflammatory infiltrate (arrows) and perifascicular atrophy (arrow heads). Original magnification 400X, scale bar 25µm.

Supporting image 3


Disclosures: A. Miguel-Álvarez: None; l. Amezcua Guerra: None; M. Loredo-Mendoza: None; L. Silveira Torre: None; A. Vargas Guerrero: None.

To cite this abstract in AMA style:

Miguel-Álvarez A, Amezcua Guerra l, Loredo-Mendoza M, Silveira Torre L, Vargas Guerrero A. Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/characterization-of-the-clinical-presentation-of-idiopathic-inflammatory-myopathies-according-to-the-profile-of-specific-autoantibodies-with-multiple-positivity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-the-clinical-presentation-of-idiopathic-inflammatory-myopathies-according-to-the-profile-of-specific-autoantibodies-with-multiple-positivity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology